percent-at-421

U.S. appeals court declines to reconsider Bank of America ruling

A U.S. appeals court refused on Monday to reconsider its decision to overturn a $1.27 billion penalty against Bank of America Corp and a jury verdict finding it liable for mortgage fraud leading up to the 2008 financial crisis. The 2nd U.S. Circuit Court of Appeals in New York rejected a petition by Manhattan U.S. Attorney Preet Bharara's office to have a three-judge panel rehear the case and give the government at least an opportunity to seek a new trial. Bharara's office had argued…

See original here: 
U.S. appeals court declines to reconsider Bank of America ruling

percent-at-421

Pfizer boosts cancer drug roster with $14 billion Medivation deal

Medivation shares were up 20 percent at $80.43 in afternoon trading, just shy of the offer price of $81.50 per share. Shares of Pfizer, the largest U.S. drugmaker, were down 0.5 percent at $34.82. The offer is a 55-percent premium to Sanofi SA's initial offer to buy Medivation for $52.50 in April that pushed the San Francisco-based company to put itself up for sale.

Original post:
Pfizer boosts cancer drug roster with $14 billion Medivation deal

percent-at-421

U.S. clearance of ChemChina’s Syngenta deal removes key hurdle

Several U.S. lawmakers and groups representing farmers had expressed fears over a Chinese state-owned company being in a position to influence the U.S. food supply. Syngenta shares jumped as much as 12.5 percent on the news and ended trading on Monday up 10.6 percent at 421.20 Swiss francs ($437.9). ChemChina's $465 per share cash offer values the company at around 448 Swiss francs per share at current exchange rates, plus a special five-franc dividend

View post:
U.S. clearance of ChemChina’s Syngenta deal removes key hurdle